HK1214501A1 - 通過糖工程的位點特異性抗體-藥物偶聯 - Google Patents
通過糖工程的位點特異性抗體-藥物偶聯Info
- Publication number
- HK1214501A1 HK1214501A1 HK16102347.8A HK16102347A HK1214501A1 HK 1214501 A1 HK1214501 A1 HK 1214501A1 HK 16102347 A HK16102347 A HK 16102347A HK 1214501 A1 HK1214501 A1 HK 1214501A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- glycoengineering
- specific antibody
- site specific
- antibody drug
- drug conjugation
- Prior art date
Links
- 229940125644 antibody drug Drugs 0.000 title 1
- 230000021615 conjugation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Virology (AREA)
- Developing Agents For Electrophotography (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361776710P | 2013-03-11 | 2013-03-11 | |
US201361776715P | 2013-03-11 | 2013-03-11 | |
US201361776724P | 2013-03-11 | 2013-03-11 | |
PCT/US2014/022728 WO2014164534A2 (en) | 2013-03-11 | 2014-03-10 | Site-specific antibody-drug conjugation through glycoengineering |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1214501A1 true HK1214501A1 (zh) | 2016-07-29 |
Family
ID=50543307
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16101117.8A HK1213271A1 (zh) | 2013-03-11 | 2016-02-01 | 高度糖基化的結合多肽 |
HK16102347.8A HK1214501A1 (zh) | 2013-03-11 | 2016-03-01 | 通過糖工程的位點特異性抗體-藥物偶聯 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16101117.8A HK1213271A1 (zh) | 2013-03-11 | 2016-02-01 | 高度糖基化的結合多肽 |
Country Status (14)
Country | Link |
---|---|
US (8) | US9580511B2 (zh) |
EP (5) | EP4098663A1 (zh) |
JP (8) | JP6739330B2 (zh) |
KR (6) | KR20240023184A (zh) |
CN (4) | CN110256560A (zh) |
AU (4) | AU2014249290B2 (zh) |
BR (2) | BR112015020315A2 (zh) |
CA (2) | CA2902530C (zh) |
HK (2) | HK1213271A1 (zh) |
IL (5) | IL275376B2 (zh) |
MX (3) | MX370356B (zh) |
RU (3) | RU2711935C2 (zh) |
SG (3) | SG11201506088RA (zh) |
WO (2) | WO2014164503A1 (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8528728B2 (en) | 2010-05-19 | 2013-09-10 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens disinfecting storage case |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
KR20240023184A (ko) | 2013-03-11 | 2024-02-20 | 젠자임 코포레이션 | 과글리코실화된 결합 폴리펩티드 |
DK3129067T3 (da) | 2014-03-19 | 2023-03-27 | Genzyme Corp | Sitespecifik glycomodificering af målsøgningsdele |
PT3204425T (pt) * | 2014-10-09 | 2020-12-18 | Genzyme Corp | Conjugados anticorpo fármaco glicomanipulados |
TN2018000324A1 (en) * | 2015-01-23 | 2020-01-16 | Sanofi Sa | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 |
CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
CA3019945A1 (en) | 2016-04-04 | 2017-10-12 | Rutgers, The State University Of New Jersey | Topoisomerase poisons |
CN106248971B (zh) * | 2016-08-19 | 2017-10-03 | 合肥瀚科迈博生物技术有限公司 | 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途 |
KR20220147721A (ko) | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
US10583191B2 (en) | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
RS65187B1 (sr) | 2016-12-19 | 2024-03-29 | Medimmune Ltd | Antitela na lif i njihove primene |
EP3568161A4 (en) | 2016-12-29 | 2020-09-02 | Development Center for Biotechnology | METHOD OF MANUFACTURING GLYCOPROTEIN DRUG CONJUGATES |
WO2018178277A1 (en) | 2017-03-29 | 2018-10-04 | Avicenna Oncology Gmbh | New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof |
JP7340517B2 (ja) * | 2017-08-31 | 2023-09-07 | シングロン エスエー | バクテリオシン及び抗菌ペプチドを作製するための方法及び組成物 |
KR102110182B1 (ko) * | 2017-09-20 | 2020-05-14 | 한양대학교 에리카산학협력단 | 신규한 옥심 유도체 화합물 및 이를 포함한 항체-약물 복합체 |
FR3085952B1 (fr) | 2018-09-17 | 2020-10-30 | Centre Nat Rech Scient | Conjugue anticorps-medicament comprenant des derives de quinoline |
US20230025327A1 (en) | 2019-06-29 | 2023-01-26 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of tubulysin derivatives and cell binding molecules and methods of making |
PT3865155T (pt) * | 2020-02-13 | 2023-01-02 | Orano Med | Processo para modificação específica de local de um anticorpo |
KR102341642B1 (ko) | 2021-06-24 | 2021-12-21 | 주식회사 글로브 | 플로어용 영상 표출 시스템 |
AU2022416272A1 (en) * | 2021-12-17 | 2024-07-18 | Fortvita Biologics (Singapore) Pte. Ltd. | Antibody-drug conjugate targeting claudin18.2 |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
EP0359096B1 (en) | 1988-09-15 | 1997-11-05 | The Trustees Of Columbia University In The City Of New York | Antibodies having modified carbohydrate content and methods of preparation and use |
JP2650358B2 (ja) | 1988-10-06 | 1997-09-03 | 株式会社ニコン | 半透過部材を有する光学装置 |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
DE69232604T2 (de) | 1992-11-04 | 2002-11-07 | City Of Hope Duarte | Antikörperkonstrukte |
US5792456A (en) * | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
ES2167391T3 (es) * | 1994-09-16 | 2002-05-16 | Merck Patent Gmbh | Inmunoconjugados ii. |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
WO1996040662A2 (en) * | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
SE9601245D0 (sv) | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
AU705063B2 (en) * | 1996-03-20 | 1999-05-13 | Immunomedics Inc. | Glycosylated humanized B-cell specific antibodies |
ES2300113T3 (es) | 1996-08-02 | 2008-06-01 | Bristol-Myers Squibb Company | Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo. |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6953675B2 (en) * | 1997-11-06 | 2005-10-11 | Immunomedics, Inc. | Landscaped antibodies and antibody fragments for clinical use |
US6001817A (en) * | 1998-01-12 | 1999-12-14 | Unitech Pharmaceuticals, Inc. | Pharmaceutical composition comprised of cisplatin, and processes for making and using same |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
WO2000017226A1 (en) | 1998-09-23 | 2000-03-30 | The Regents Of The University Of California | Synthetic peptides, conjugation reagents and methods |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
CN1110322C (zh) * | 1999-07-21 | 2003-06-04 | 中国医学科学院医药生物技术研究所 | 单克隆抗体Fab'-平阳霉素偶联物及其抗肿瘤作用 |
CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
US20050107595A1 (en) * | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
US7173003B2 (en) * | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7226903B2 (en) * | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
EP2305311A3 (en) * | 2001-10-10 | 2011-07-20 | BioGeneriX AG | Glycoconjugation of peptides |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
IL161251A0 (en) * | 2001-10-10 | 2004-09-27 | Neose Technologies Inc | Remodeling and glycoconjugation of peptides |
US7265084B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7795210B2 (en) * | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7696163B2 (en) * | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
EP1487879B1 (en) | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20070207142A1 (en) * | 2002-05-08 | 2007-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
EP2364996B1 (en) | 2002-09-27 | 2016-11-09 | Xencor Inc. | Optimized FC variants and methods for their generation |
CA2502904C (en) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP2338333B1 (en) * | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Glycopegylation methods and proteins/peptides produced by the methods |
JP4629047B2 (ja) | 2003-06-12 | 2011-02-09 | イーライ リリー アンド カンパニー | Glp−1アナログ複合タンパク質 |
EP1664116A4 (en) | 2003-08-22 | 2009-06-03 | Biogen Idec Inc | IMPROVED ANTIBODIES WITH CHANGED EFFECTOR FUNCTION AND MANUFACTURING METHOD THEREFOR |
RU2392324C2 (ru) | 2003-09-18 | 2010-06-20 | Симфоген А/С | Способ связывания интересующих последовательностей |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
PT1725249E (pt) | 2003-11-06 | 2014-04-10 | Seattle Genetics Inc | Compostos de monometilvalina capazes de conjugação a ligandos |
CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
US7001978B2 (en) | 2003-11-19 | 2006-02-21 | Xerox Corporation | Unsaturated ester substituted polymers with reduced halogen content |
CA2548817A1 (en) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
US8361961B2 (en) * | 2004-01-08 | 2013-01-29 | Biogenerix Ag | O-linked glycosylation of peptides |
DK1706424T3 (da) | 2004-01-12 | 2009-11-02 | Applied Molecular Evolution | FC-region varianter |
AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
ES2339953T5 (es) | 2004-05-04 | 2020-05-06 | Novo Nordisk Healthcare Ag | Glicoformas de factor VII ligadas a O y método de fabricación |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
ES2530340T3 (es) | 2004-07-15 | 2015-03-02 | Xencor Inc | Variantes de Fc optimizadas |
DK1791565T3 (en) * | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
AU2005289594B2 (en) | 2004-09-27 | 2012-02-02 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
JP4829609B2 (ja) | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
CN101160326B (zh) | 2005-02-23 | 2013-04-10 | 利普生技术有限公司 | 用于蛋白质衍生和缀合的活化的唾液酸衍生物 |
DK2343320T3 (da) | 2005-03-25 | 2018-01-29 | Gitr Inc | Anti-gitr-antistoffer og anvendelser deraf |
CA2602663A1 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc variants with optimized properties |
JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するFc変異体 |
ES2523666T3 (es) | 2005-05-31 | 2014-11-28 | Board Of Regents, The University Of Texas System | Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos |
US8901281B2 (en) | 2005-06-17 | 2014-12-02 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
SG163548A1 (en) | 2005-06-30 | 2010-08-30 | Centocor Inc | Methods and compositions with enhanced therapeutic activity |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7846724B2 (en) * | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
KR20090027227A (ko) * | 2006-06-06 | 2009-03-16 | 제넨테크, 인크. | 항-dll4 항체 및 이의 사용 방법 |
US7777008B2 (en) | 2006-06-19 | 2010-08-17 | Tolerx, Inc. | ILT3 binding molecules and uses therefor |
US8460364B2 (en) | 2006-07-20 | 2013-06-11 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
EP2049144B8 (en) * | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
FI20060946A0 (fi) * | 2006-10-26 | 2006-10-26 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
JP2010512306A (ja) * | 2006-10-27 | 2010-04-22 | ザ ロックフェラー ユニバーシティー | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
PE20081250A1 (es) | 2006-11-28 | 2008-10-07 | Centelion | FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA |
MX2009007375A (es) | 2007-01-09 | 2009-07-21 | Biogen Idec Inc | Anticuerpos sp35 y usos de los mismos. |
AU2008207898B2 (en) | 2007-01-23 | 2012-05-03 | Xencor, Inc | Optimized CD40 antibodies and methods of using the same |
CN101687037B (zh) | 2007-05-08 | 2013-07-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗muc16抗体和抗体药物偶联物 |
DK2205258T3 (en) * | 2007-09-28 | 2017-08-28 | Janssen Biotech Inc | Method and structural conformations of antibody preparations with increased resistance to proteases |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
AU2008312457B2 (en) | 2007-10-19 | 2014-04-17 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
EP2242505A4 (en) * | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
ES2587392T3 (es) | 2008-01-31 | 2016-10-24 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
US20110137011A1 (en) | 2008-04-21 | 2011-06-09 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
CA2735193A1 (en) | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
EP2233499A1 (en) | 2009-03-26 | 2010-09-29 | CSL Behring AG | Antibody composition with altered Fab sialylation |
US10087236B2 (en) * | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
CN102812039B (zh) | 2010-02-16 | 2016-01-20 | 诺沃—诺迪斯克有限公司 | 缀合蛋白质 |
EA030226B1 (ru) | 2010-03-04 | 2018-07-31 | Макродженикс, Инк. | Антитела, реактивные к b7-h3, их иммунологически активные фрагменты и их применения |
CN103119064B (zh) * | 2010-08-10 | 2018-09-04 | 葛莱高托普有限公司 | Fab糖基化抗体 |
AR085302A1 (es) * | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
JP2014528901A (ja) | 2011-03-11 | 2014-10-30 | アミカス セラピューティックス インコーポレイテッド | ファブリー病の治療用投薬レジメン |
TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
RS64317B1 (sr) | 2012-09-12 | 2023-08-31 | Genzyme Corp | Polipeptidi sa izmenjenom glikozilacijom i smanjenom efektorskom funkcijom koji sadrže fc |
KR20240023184A (ko) | 2013-03-11 | 2024-02-20 | 젠자임 코포레이션 | 과글리코실화된 결합 폴리펩티드 |
DK3129067T3 (da) | 2014-03-19 | 2023-03-27 | Genzyme Corp | Sitespecifik glycomodificering af målsøgningsdele |
EP3129402A4 (en) | 2014-04-08 | 2017-12-13 | University Of Georgia Research Foundation, Inc. | Site-specific antibody-drug glycoconjugates and methods |
PT3204425T (pt) | 2014-10-09 | 2020-12-18 | Genzyme Corp | Conjugados anticorpo fármaco glicomanipulados |
EP3947458A1 (en) | 2019-04-03 | 2022-02-09 | Genzyme Corporation | Anti-alpha beta tcr binding polypeptides with reduced fragmentation |
-
2014
- 2014-03-10 KR KR1020247003596A patent/KR20240023184A/ko active Application Filing
- 2014-03-10 SG SG11201506088RA patent/SG11201506088RA/en unknown
- 2014-03-10 US US14/203,479 patent/US9580511B2/en active Active
- 2014-03-10 MX MX2015012570A patent/MX370356B/es active IP Right Grant
- 2014-03-10 EP EP22171935.4A patent/EP4098663A1/en active Pending
- 2014-03-10 CA CA2902530A patent/CA2902530C/en active Active
- 2014-03-10 SG SG11201506086SA patent/SG11201506086SA/en unknown
- 2014-03-10 WO PCT/US2014/022623 patent/WO2014164503A1/en active Application Filing
- 2014-03-10 CN CN201910427632.9A patent/CN110256560A/zh active Pending
- 2014-03-10 KR KR1020217037637A patent/KR102494631B1/ko active IP Right Grant
- 2014-03-10 KR KR1020237003194A patent/KR20230020013A/ko not_active Application Discontinuation
- 2014-03-10 KR KR1020227023776A patent/KR20220103204A/ko not_active Application Discontinuation
- 2014-03-10 EP EP22151876.4A patent/EP4063389A3/en active Pending
- 2014-03-10 JP JP2016501017A patent/JP6739330B2/ja active Active
- 2014-03-10 RU RU2015142992A patent/RU2711935C2/ru active
- 2014-03-10 CN CN201480014338.0A patent/CN105228645B/zh active Active
- 2014-03-10 KR KR1020157027622A patent/KR102330681B1/ko active IP Right Grant
- 2014-03-10 US US14/203,438 patent/US9701753B2/en active Active
- 2014-03-10 BR BR112015020315A patent/BR112015020315A2/pt not_active Application Discontinuation
- 2014-03-10 EP EP14718808.0A patent/EP2983701A2/en not_active Withdrawn
- 2014-03-10 IL IL275376A patent/IL275376B2/en unknown
- 2014-03-10 JP JP2016501047A patent/JP6588422B2/ja active Active
- 2014-03-10 KR KR1020157027621A patent/KR102420934B1/ko active IP Right Grant
- 2014-03-10 AU AU2014249290A patent/AU2014249290B2/en active Active
- 2014-03-10 CA CA2902525A patent/CA2902525C/en active Active
- 2014-03-10 CN CN201480014449.1A patent/CN105189555B/zh active Active
- 2014-03-10 CN CN202010633677.4A patent/CN111875705B/zh active Active
- 2014-03-10 RU RU2015143057A patent/RU2708314C2/ru active
- 2014-03-10 RU RU2020100459A patent/RU2020100459A/ru unknown
- 2014-03-10 EP EP18187892.7A patent/EP3424956A1/en not_active Withdrawn
- 2014-03-10 MX MX2015012527A patent/MX370679B/es active IP Right Grant
- 2014-03-10 BR BR112015020885A patent/BR112015020885A2/pt not_active Application Discontinuation
- 2014-03-10 AU AU2014249224A patent/AU2014249224B2/en active Active
- 2014-03-10 WO PCT/US2014/022728 patent/WO2014164534A2/en active Application Filing
- 2014-03-10 SG SG10201809779RA patent/SG10201809779RA/en unknown
- 2014-03-10 EP EP14714881.1A patent/EP2970469B1/en active Active
-
2015
- 2015-09-02 IL IL241084A patent/IL241084B/en unknown
- 2015-09-02 IL IL241085A patent/IL241085B/en active IP Right Grant
- 2015-09-11 MX MX2019014833A patent/MX2019014833A/es unknown
-
2016
- 2016-02-01 HK HK16101117.8A patent/HK1213271A1/zh unknown
- 2016-03-01 HK HK16102347.8A patent/HK1214501A1/zh unknown
-
2017
- 2017-01-27 US US15/417,648 patent/US10214589B2/en active Active
- 2017-06-05 US US15/614,015 patent/US10494439B2/en active Active
-
2018
- 2018-12-21 AU AU2018282451A patent/AU2018282451B2/en active Active
-
2019
- 2019-01-03 US US16/238,932 patent/US11130816B2/en active Active
- 2019-03-06 JP JP2019040108A patent/JP7121675B2/ja active Active
- 2019-09-11 JP JP2019165052A patent/JP7021159B2/ja active Active
- 2019-10-17 US US16/655,500 patent/US11807690B2/en active Active
-
2021
- 2021-04-14 JP JP2021068088A patent/JP7321206B2/ja active Active
- 2021-05-27 AU AU2021203458A patent/AU2021203458A1/en active Pending
- 2021-08-17 US US17/404,412 patent/US20220089763A1/en active Pending
-
2022
- 2022-01-17 IL IL289918A patent/IL289918A/en unknown
- 2022-02-02 JP JP2022014608A patent/JP7390414B2/ja active Active
-
2023
- 2023-05-01 JP JP2023075428A patent/JP2023099146A/ja active Pending
- 2023-07-25 IL IL304738A patent/IL304738A/en unknown
- 2023-09-07 US US18/463,047 patent/US20240182595A1/en active Pending
- 2023-11-17 JP JP2023195664A patent/JP2024020447A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1214501A1 (zh) | 通過糖工程的位點特異性抗體-藥物偶聯 | |
IL274881A (en) | Anti-EGFR antibody and drug conjugate formulations | |
IL241277A0 (en) | Antibody-drug conjugates | |
IL259651A (en) | Conjugations between an antibody to a specific her2 site and a drug | |
HK1217956A1 (zh) | 新的抗體綴合物及其用途 | |
ZA201508487B (en) | Antibody drug conjugates | |
SG10202002153PA (en) | Glycoengineered antibody drug conjugates | |
IL252015A0 (en) | Antibody drug conjugates | |
IL250189A0 (en) | Anti–cdh6 antibody drug conjugates | |
IL236323B (en) | Drug conjugates of anti–cd70 antibody | |
EP2968600A4 (en) | Antibody drug conjugates | |
LU92659B1 (en) | Glycooptimized antibody drug conjugates | |
SG11201506358PA (en) | Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof | |
SG11201604503XA (en) | Cytotoxic antibody |